Company intelligence / Profile preview

Damewood Therapeutics

Alpharetta, Georgia, United Statesdamewoodtherapeutics.com ↗

Ownership: Private
Employees: ~12
Development stage: Commercial

Overview

Dogwood Therapeutics develops novel therapeutics for pain and fatigue-related disorders. Its lead asset Halneuron, an injectable Tetrodotoxin-based small molecule Nav1.7 inhibitor, has reached Phase 2b for chemotherapy-induced neuropathic and cancer-related pain. IMC‑1—a fixed-dose combination of famciclovir and celecoxib—has completed Phase 2b for fibromyalgia and received FDA fast track designation; it’s ready for Phase 3 trials. IMC‑2—a valacyclovir plus celecoxib combo—is in Phase 2 development targeting Long-COVID/PASC. The company was formerly known as Virios Therapeutics until October 2024.

Therapeutic areas: OncologyRheumatologyOphthalmologyNeurologyInfectious Diseases
Modalities: Small moleculeCombination therapyAntiviral therapyNon-opioid analgesic
Industry: Biotech

Beyond the preview

Go deeper on Damewood Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Damewood Therapeutics.

Explore the full profile